The prevalence of invasive fungal infections (IFIs) has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. These infections are associated with significant morbidity and mortality. Recent significant advances in antifungal therapy include the broad-spectrum triazoles (voriconazole and posaconazole) and a new class of antifungals, the echinocandins (caspofungin, micafungin, and anidulafungin). New treatment strategies, such as combination therapy and pre-emptive therapy, are being investigated. There have also been significant improvements in diagnostics; the galactomannan enzyme immunoassay and the beta-glucan test are now part of the EORTC/MSG criteria for diagnosis of IFI. Despite these advances, there remain a number of unanswered questions regarding optimal management of serious fungal infections, and research continues to discover and develop new therapies and evaluate new management strategies.

中文翻译：

---

抗真菌治疗的进展。

在过去的三十年中，由于免疫功能低下的宿主数量的增加，侵袭性真菌感染的发生率有所增加。这些感染与明显的发病率和死亡率有关。抗真菌疗法的最新重大进展包括广谱三唑（伏立康唑和泊沙康唑）和一类新型抗真菌剂棘球chin素（卡泊芬净，米卡芬净和阿尼芬净）。正在研究诸如联合疗法和先发制人疗法的新治疗策略。诊断方面也有了重大改进；现在，半乳甘露聚糖酶免疫测定和β-葡聚糖检测已成为诊断IFI的EORTC / MSG标准的一部分。尽管取得了这些进展，但有关严重真菌感染的最佳管理方面仍存在许多未解决的问题，